The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

Marc van Bilsen, Hitesh C. Patel, Johann Bauersachs, Michael Böhm, Martin Borggrefe, Dirk Brutsaert, Andrew J.S. Coats, Rudolf A. de Boer, Gilles W. de Keulenaer, Gerasimos S. Filippatos, John Floras, Guido Grassi, Ewa A. Jankowska, Lilian Kornet, Ida G. Lunde, Christoph Maack, Felix Mahfoud, Piero Pollesello, Piotr Ponikowski, Frank RuschitzkaHani N. Sabbah, Harold D. Schultz, Petar Seferovic, Riemer H.J.A. Slart, Peter Taggart, Carlo G. Tocchetti, Linda W. Van Laake, Faiez Zannad, Stephane Heymans, Alexander R. Lyon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Despite improvements in medical therapy and device-based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?.

Original languageEnglish (US)
Pages (from-to)1361-1378
Number of pages18
JournalEuropean Journal of Heart Failure
Volume19
Issue number11
DOIs
StatePublished - Nov 2017

Fingerprint

Translational Medical Research
Autonomic Nervous System
Heart Failure
Therapeutics
Equipment and Supplies
Treatment Failure
Electric Stimulation
Disease Progression
Heart Diseases
Patient Care
Delivery of Health Care
Education

Keywords

  • Autonomic dysfunction
  • Devices and nerve ablation
  • Heart failure
  • Parasympathetic
  • Sympathetic

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The autonomic nervous system as a therapeutic target in heart failure : a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. / van Bilsen, Marc; Patel, Hitesh C.; Bauersachs, Johann; Böhm, Michael; Borggrefe, Martin; Brutsaert, Dirk; Coats, Andrew J.S.; de Boer, Rudolf A.; de Keulenaer, Gilles W.; Filippatos, Gerasimos S.; Floras, John; Grassi, Guido; Jankowska, Ewa A.; Kornet, Lilian; Lunde, Ida G.; Maack, Christoph; Mahfoud, Felix; Pollesello, Piero; Ponikowski, Piotr; Ruschitzka, Frank; Sabbah, Hani N.; Schultz, Harold D.; Seferovic, Petar; Slart, Riemer H.J.A.; Taggart, Peter; Tocchetti, Carlo G.; Van Laake, Linda W.; Zannad, Faiez; Heymans, Stephane; Lyon, Alexander R.

In: European Journal of Heart Failure, Vol. 19, No. 11, 11.2017, p. 1361-1378.

Research output: Contribution to journalArticle

van Bilsen, M, Patel, HC, Bauersachs, J, Böhm, M, Borggrefe, M, Brutsaert, D, Coats, AJS, de Boer, RA, de Keulenaer, GW, Filippatos, GS, Floras, J, Grassi, G, Jankowska, EA, Kornet, L, Lunde, IG, Maack, C, Mahfoud, F, Pollesello, P, Ponikowski, P, Ruschitzka, F, Sabbah, HN, Schultz, HD, Seferovic, P, Slart, RHJA, Taggart, P, Tocchetti, CG, Van Laake, LW, Zannad, F, Heymans, S & Lyon, AR 2017, 'The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology', European Journal of Heart Failure, vol. 19, no. 11, pp. 1361-1378. https://doi.org/10.1002/ejhf.921
van Bilsen, Marc ; Patel, Hitesh C. ; Bauersachs, Johann ; Böhm, Michael ; Borggrefe, Martin ; Brutsaert, Dirk ; Coats, Andrew J.S. ; de Boer, Rudolf A. ; de Keulenaer, Gilles W. ; Filippatos, Gerasimos S. ; Floras, John ; Grassi, Guido ; Jankowska, Ewa A. ; Kornet, Lilian ; Lunde, Ida G. ; Maack, Christoph ; Mahfoud, Felix ; Pollesello, Piero ; Ponikowski, Piotr ; Ruschitzka, Frank ; Sabbah, Hani N. ; Schultz, Harold D. ; Seferovic, Petar ; Slart, Riemer H.J.A. ; Taggart, Peter ; Tocchetti, Carlo G. ; Van Laake, Linda W. ; Zannad, Faiez ; Heymans, Stephane ; Lyon, Alexander R. / The autonomic nervous system as a therapeutic target in heart failure : a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. In: European Journal of Heart Failure. 2017 ; Vol. 19, No. 11. pp. 1361-1378.
@article{004c355a1efb4088ae96df6284ff6ce2,
title = "The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology",
abstract = "Despite improvements in medical therapy and device-based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?.",
keywords = "Autonomic dysfunction, Devices and nerve ablation, Heart failure, Parasympathetic, Sympathetic",
author = "{van Bilsen}, Marc and Patel, {Hitesh C.} and Johann Bauersachs and Michael B{\"o}hm and Martin Borggrefe and Dirk Brutsaert and Coats, {Andrew J.S.} and {de Boer}, {Rudolf A.} and {de Keulenaer}, {Gilles W.} and Filippatos, {Gerasimos S.} and John Floras and Guido Grassi and Jankowska, {Ewa A.} and Lilian Kornet and Lunde, {Ida G.} and Christoph Maack and Felix Mahfoud and Piero Pollesello and Piotr Ponikowski and Frank Ruschitzka and Sabbah, {Hani N.} and Schultz, {Harold D.} and Petar Seferovic and Slart, {Riemer H.J.A.} and Peter Taggart and Tocchetti, {Carlo G.} and {Van Laake}, {Linda W.} and Faiez Zannad and Stephane Heymans and Lyon, {Alexander R.}",
year = "2017",
month = "11",
doi = "10.1002/ejhf.921",
language = "English (US)",
volume = "19",
pages = "1361--1378",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The autonomic nervous system as a therapeutic target in heart failure

T2 - a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

AU - van Bilsen, Marc

AU - Patel, Hitesh C.

AU - Bauersachs, Johann

AU - Böhm, Michael

AU - Borggrefe, Martin

AU - Brutsaert, Dirk

AU - Coats, Andrew J.S.

AU - de Boer, Rudolf A.

AU - de Keulenaer, Gilles W.

AU - Filippatos, Gerasimos S.

AU - Floras, John

AU - Grassi, Guido

AU - Jankowska, Ewa A.

AU - Kornet, Lilian

AU - Lunde, Ida G.

AU - Maack, Christoph

AU - Mahfoud, Felix

AU - Pollesello, Piero

AU - Ponikowski, Piotr

AU - Ruschitzka, Frank

AU - Sabbah, Hani N.

AU - Schultz, Harold D.

AU - Seferovic, Petar

AU - Slart, Riemer H.J.A.

AU - Taggart, Peter

AU - Tocchetti, Carlo G.

AU - Van Laake, Linda W.

AU - Zannad, Faiez

AU - Heymans, Stephane

AU - Lyon, Alexander R.

PY - 2017/11

Y1 - 2017/11

N2 - Despite improvements in medical therapy and device-based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?.

AB - Despite improvements in medical therapy and device-based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?.

KW - Autonomic dysfunction

KW - Devices and nerve ablation

KW - Heart failure

KW - Parasympathetic

KW - Sympathetic

UR - http://www.scopus.com/inward/record.url?scp=85030468745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030468745&partnerID=8YFLogxK

U2 - 10.1002/ejhf.921

DO - 10.1002/ejhf.921

M3 - Article

C2 - 28949064

AN - SCOPUS:85030468745

VL - 19

SP - 1361

EP - 1378

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -